Abstract
Stratification by P21+/MCM2− status identifies differential responses to sorafenib in intermediate- and high-risk ccRCC. In patients with ≤2% P21+/MCM2− cells, no significant benefit from sorafenib was observed (left). In contrast, patients with >2% of these cells had significantly worse outcomes when treated with sorafenib compared with placebo (right; P < 0.001).